In a post hoc analysis of three studies, IL-6R inhibition with sarilumab was associated with a reduction in HbA1c in patients with RA with and without comorbid diabetes that were greater than with placebo or adalimumab and could not be attributed solely to changes in CRP, disease activity or haemoglobin. This evidence concerns the gene CRP and diabetes mellitus.